In late 2021, the omicron variant of SARS Coronavirus 2 (SARS-CoV-2) emerged and replaced the previously dominant delta strain. Effectiveness of COVID-19 vaccines against omicron has been challenging to estimate in clinical studies or is not available for all vaccines or populations of interest. T cell function can be predictive of vaccine longevity and effectiveness against disease, likely in a more robust way than antibody neutralization. In this mini review, we summarize the evidence on T cell immunity against omicron including effects of boosters, homologous versus heterologous regimens, hybrid immunity, memory responses and vaccine product. Overall, T cell reactivity in post-vaccine specimens is largely preserved against omicron, indicating that vaccines utilizing the parental antigen continue to be protective against disease caused by the omicron variant.
CITATION STYLE
Jacobsen, H., Cobos Jiménez, V., Sitaras, I., Bar-Zeev, N., Čičin-Šain, L., Higdon, M. M., & Deloria-Knoll, M. (2022, July 26). Post-vaccination T cell immunity to omicron. Frontiers in Immunology. Frontiers Media S.A. https://doi.org/10.3389/fimmu.2022.944713
Mendeley helps you to discover research relevant for your work.